Reduced Level of CD44 and Hyaluronan Associated With Unfavorable Prognosis in Clinical Stage I Cutaneous Melanoma

American Journal of Pathology - United States
doi 10.1016/s0002-9440(10)64608-1
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

High LIFr Expression Stimulates Melanoma Cell Migration and Is Associated With Unfavorable Prognosis in Melanoma

Oncotarget
Oncology
2015English

Revisiting Determinants of Prognosis in Cutaneous Melanoma

Cancer
Cancer ResearchOncology
2015English

The Hyaluronan Receptor (CD44) Participates in the Uptake and Degradation of Hyaluronan

Journal of Cell Biology
MedicineCell Biology
1992English

Inflammation Markers in Cutaneous Melanoma - Edgy Biomarkers for Prognosis

Discoveries
2015English

Us Burden of Illness Associated With Adjuvant Therapy for Stage I-Iii Melanoma

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

DLC1 Expression Is Reduced in Human Cutaneous Melanoma and Correlates With Patient Survival

Modern Pathology
Forensic MedicinePathology
2014English

Serum Calcium, Albumin and Tumor Stage in Cutaneous Malignant Melanoma

Future Oncology
MedicineCancer ResearchOncology
2016English

Reduced Expression of SRY-box Containing Gene 17 Correlates With an Unfavorable Melanoma Patient Survival

Oncology Reports
MedicineCancer ResearchOncology
2014English

Comment on “Improving Clinical Diagnosis of Early-Stage Cutaneous Melanoma Based on Raman Spectroscopy”

British Journal of Cancer
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy